Application of gecacitinib hydrochloride tablets in treatment of myelofibrosis

VernacularTitle:盐酸吉卡昔替尼片在骨髓纤维化治疗中的应用
Author: Yi ZHANG ¹ ; Hu ZHOU ; Zhijian XIAO ; Jie JIN
Author Information

1. 浙江大学附属第一医院血液科，杭州　310003
Keywords: Myelofibrosis; Gecacitinib hydrochloride tablets; JAK inhibitor; Anemia; Treatment outcome
From: Journal of Leukemia & Lymphoma 2024;33(7):392-398
CountryChina
Language:Chinese
Abstract: Gecacitinib hydrochloride tablets (gecacitinib for short, and formerly known as "jaktinib hydrochloride tablets") is a novel JAK and ACVR1 inhibitor, which not only blocks the JAK-STAT signaling pathway by inhibiting the activities of JAK1, JAK2, JAK3, and TYK2, thereby alleviating inflammation and splenomegaly symptoms, but also reduces hepcidin transcription by inhibiting ACVR1 activity, thereby improving iron metabolism imbalance and anemia. Data from phases Ⅱ and Ⅲ clinical trials suggest that gecacitinib can both alleviate splenomegaly and reduce constitutional symptoms in patients with myelofibrosis (MF) who are na?ve to JAK inhibitors or have been exposed to ruxolitinib, as well as improve anemia in patients with MF. This article describes the mechanisms of action, pharmacokinetic characteristics, clinical efficacy, and treatment-related adverse effects of gecacitinib in the treatment of MF, providing references for the rational application of this drug in MF.